CRISPR Therapies Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Intellia, CRISPR Therapeutics, Caribou, Emendo, Sarepta, Editas, AstraZeneca

DelveInsight Business Research LLP
As per DelveInsight’s assessment, globally, about 25+ key pharma and biotech companies are working on 30+ pipeline drugs in the CRISPR therapeutics market. Several of the CRISPR therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

CRISPR Therapies Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the CRISPR Therapies Market. 

The CRISPR Therapies Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

CRISPR Therapies Pipeline Analysis

The report provides insights into: 

The report provides detailed insights into emerging therapies in the CRISPR Market and the aggregate therapies developed by major pharma companies.

It accesses the different CRISPR therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development.

It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the CRISPR Therapies Market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, featured press releases from company/university websites, industry-specific third-party sources, etc.  

Learn How the Ongoing Clinical & Commercial Activities will Affect the CRISPR Therapies Therapeutic Segment @

Phases of Emerging Therapies

DelveInsight’s Report covers around 30+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

CRISPR Therapies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as






Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody



Small molecule

Gene therapy

CRISPR Therapies Therapeutics Landscape

There are approx. 25+ key companies which are developing CRISPR Therapies. Currently, CRISPR Therapeutics is leading the therapeutics market with its CRISPR Therapies drug candidates in the most advanced stage of clinical development.

Leading CRISPR Therapies Companies in the Therapeutics Market Include:

Intellia Therapeutics

CRISPR therapeutics

Repare Therapeutics

Beam therapeutics

Caribou Biosciences

Emendo Biotherapeutics

Defence Therapeutics

Sarepta therapeutics

Editas Medicine

Locus Biosciences

Excision BioTherapeutics



ASC therapeutics

Casebia therapeutics

Spotlight Therapeutics

KSQ Therapeutics

MEDIC Life Sciences

Scribe therapeutics

Arbor Biotechnologies

Sangamo therapeutics

Graphite Bio

Nuntius Therapeutics

And Many Others

CRISPR Therapies Emerging and Marketed Drugs Covered in the Report Include:

CTX001: CRISPR Therapeutics

EDIT-101: Editas Medicine

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. CRISPR Therapies Current Treatment Patterns

4. CRISPR Therapies – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. CRISPR Therapies Late Stage Products (Phase-III)

7. CRISPR Therapies Mid-Stage Products (Phase-II)

8. CRISPR Therapies Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. CRISPR Therapies Discontinued Products

13. CRISPR Therapies Product Profiles

14. CRISPR Therapies Companies in the Market

15. Key Products in the CRISPR Therapies Therapeutics Segment

16. Dormant and Discontinued Products

17. CRISPR Therapies Unmet Needs

18. CRISPR Therapies Future Perspectives

19. CRISPR Therapies Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.


Other Trending Healthcare Reports By DelveInsight

Traveler’s Diarrhea Market

“Traveler’s Diarrhea Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Traveler’s Diarrhea market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Traveler’s Diarrhea market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

%d bloggers like this: